Guidelines drive prescribing patterns, insurance coverage decisions, and prior authorization criteria. When ADA, AACE, and The Obesity Society update their recommendations, the downstream effects reach every patient seeking GLP-1 treatment. The 2025-2026 updates reflect the rapid evolution of obesity pharmacotherapy — and the guidelines are catching up to the data.
What all three guidelines now agree on
GLP-1 agonists are first-line pharmacotherapy for obesity. All three bodies now position semaglutide 2.4mg and tirzepatide as preferred first-line options for patients meeting BMI criteria (≥30, or ≥27 with comorbidities). This is a shift from the previous framing where pharmacotherapy was positioned as adjunctive to lifestyle intervention — now it's recommended alongside lifestyle changes from the initial treatment decision.
Weight loss goals should be individualized. Previous guidelines set broad targets (5-10% body weight loss as "clinically meaningful"). Updated guidelines emphasize individual patient goals and comorbidity-specific thresholds — for example, 10-15% loss for GERD resolution, 15-20% for obstructive sleep apnea improvement, and 20%+ for potential Type 2 diabetes remission.
Long-term medication is expected. All three guidelines now explicitly state that obesity is a chronic disease requiring long-term management. The implication: discontinuing GLP-1 medication is expected to result in weight regain, and long-term pharmacotherapy is the standard of care, not a temporary intervention.
Where the guidelines diverge
| Topic | ADA | AACE | Obesity Society |
|---|---|---|---|
| Compounded GLP-1s | No position | Discourages (cites quality concerns) | Acknowledges access role |
| Combination therapy | Mentions emerging data | Endorses sequential escalation | Supports evidence-based combos |
| Surgery thresholds | BMI ≥35, or ≥30 + comorbidities | BMI ≥30, or ≥27 in Asian patients | BMI ≥35 preferred |
| Pediatric pharmacotherapy | ≥12 years for semaglutide | ≥12 with careful monitoring | Case-by-case assessment |
| Cardiovascular benefit emphasis | Strong (SELECT data) | Strong | Moderate |
The compounding question
The most clinically relevant divergence is on compounded GLP-1 medications. AACE's discouragement of compounded products cites concerns about product quality, consistency, and sterility assurance. The Obesity Society's more nuanced position acknowledges that compounded medications fill an access gap for patients who cannot afford brand-name products or who lack insurance coverage.
Neither position is wrong. Both are incomplete. The quality concern is legitimate — not all compounding pharmacies meet the same standards. The access argument is equally legitimate — patients without $800-1,300/month for brand-name GLP-1s have limited alternatives. The guidelines would serve patients better by distinguishing between well-regulated 503A/503B compounders and unregulated sources, rather than taking blanket positions.
The 2025-2026 guideline updates represent the most significant shift in obesity treatment recommendations in a decade. GLP-1 agonists are now unambiguously first-line, long-term therapy is the standard expectation, and cardiovascular benefit data is reshaping how obesity is treated as a cardiometabolic disease rather than a lifestyle condition.